Steiner, George

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS)

Ansquer, J.-C., Foucher, C., Rattier, S., Taskinen, M.-R., & Steiner, G. (2005) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 264

Rate of production of plasma and very-low-density lipoprotein (VLDL) apolipoprotein C-III is strongly related to the concentration and level of production of VLDL triglyceride in male subjects with different body weights and levels of insulin sensitivity.

Cohn, J. S., Patterson, B. W., Uffelman, K. D., Davignon, J., & Steiner, G. (2004) · The Journal of Clinical Endocrinology & Metabolism

Lipid metabolism and disordersDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 170

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

Genest, J., Frohlich, J., & Steiner, G. (2004) · The American Journal of Cardiology

Folate and B Vitamins ResearchLipoproteins and Cardiovascular Health

Cited by 51

Fenofibrate Lowers Plasma Triglycerides and Increases LDL Particle Diameter in Subjects With Type 2 Diabetes

Vakkilainen, J., Steiner, G., Ansquer, J.-C., Perttunen-Nio, H., & Taskinen, M.-R. (2002) · Diabetes Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 40